Flagging up a neglected killer  by Williams, Nigel
Current Biology Vol 19 No 15
R628Features
This year marks the centenary of the discovery by the Brazilian doctor Carlos 
Chagas of the parasite and insect vectors which cause the disease that carries 
his name. A new campaign aims to boost work on this major infection in Latin 
America. Nigel Williams reports.
Flagging up a neglected killerWhile this year has seen celebrations 
commemorating the centenary of 
Carlos Chagas’ discovery of the 
parasite disease that bears his name, 
considered a landmark in Brazilian 
science, current research on the 
disease is seriously lacking. A recent 
study has found that less than 
0.5 per cent of worldwide research and 
development into neglected diseases 
in 2007 was aimed at Chagas disease, 
according to the medical charity, 
Médicins Sans Frontières (MSF). In this 
centenary year, MSF is launching a 
campaign to highlight the neglect the 
disease has received and calls for major 
new education and research initiatives 
to help tackle it.
Chagas disease is an infectious 
disease caused by the Trypanosoma 
cruzi parasite, which was named by 
Chagas after his mentor, parasitologist Oswaldo Cruz. Endemic in several 
Latin American countries, cases 
are found in rural areas, indigenous 
communities and the poorest suburbs 
from Mexico to Argentina, including 
parts of the Caribbean. The disease 
causes an estimated 14,000 deaths 
each year. It is estimated that 10–15 
million people suffer from the disease 
and 100 million more, 25 per cent of 
the population of Latin America, are at 
risk of contracting it.
As a result of the increase in global 
migration and mobility, an increasing 
number of cases are being reported in 
the US, Europe, Australia and Japan.
The parasite is transmitted by 
certain species of the Triatominae 
‘assassin bugs’ or ‘kissing bugs’ 
depending on geographical zone. The 
insects live in cracks in the walls and 
ceilings of houses made from adobe bricks, sticks, straw and other basic 
materials and emerge at night to feed 
on blood. When an assassin bug 
carrying the parasite bites a person, 
it deposits faeces on the skin. If the 
person scratches or rubs their eyes 
or mouth after touching the bite, 
the parasites can then pass into the 
bloodstream. If an infected person is 
bitten by another assassin bug, the 
parasite infects the insect and the 
cycle goes on.
In many Latin American countries, 
prevention programmes are being 
developed with the aim of reducing 
the presence of the insect vector, but 
not all of them are as effective as they 
could be and they have proved mostly 
unable to eliminate the disease.
Chagas disease can also 
be transmitted through blood 
transfusions, from mothers to 
children during pregnancy and, less 
frequently, through organ transplants 
or consumption of contaminated food. 
It is not transmitted through direct 
contact with infected individuals.Challenging: An MSF doctor testing a child for Chagas in rural Bolivia. (Photo: MSF/Juan Carlos Tomasi.)
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We all hope we are capable of making 
rational choices and we particularly 
expect it from others, especially 
those in positions of power and 
infl uence. Indeed, economic models 
of animal behaviour assume that 
decision- makers are rational, meaning 
that they assess options according 
to intrinsic fi tness value, and not by 
comparison to available alternatives.
However, unsurprisingly, this 
expectation frequently fails, but the 
signifi cance of irrational behaviour 
remains controversial. One possibility 
is that irrationality arises from 
cognitive constraints that necessitate 
short cuts like comparative evaluation 
of available choices. If so, the study of 
whether and when irrationality occurs 
can illuminate cognitive mechanisms.
A basic assumption of behavioural 
ecology is that animals act to 
maximise their fi tness. To do so, 
a rational decision-maker must 
consistently value each option on the 
basis of its contribution to utility. In a 
biological setting, rationality implies 
that decision-making animals should 
assign value according to an option’s 
net fi tness benefi ts. For example, an 
animal that prefers food type A to type 
B should not switch preference to B if 
a third type C is also made available.
However, experiments with humans 
and animals reveal widespread 
irrationality which appears to cast 
doubt on the idea that individuals 
maximise either utility or fi tness.
Recent theoretical work also shows 
that even optimal brains of high 
complexity will be error-prone in the 
information-rich environments typical 
of real animals, write researchers 
Susan Edwards and Stephen Pratt.
In a new study, Edwards at 
Princeton University and Pratt at 
Arizona State University, reporting in 
the Proceedings of the Royal Society 
B (published online), have looked 
at the collective decisions of insect 
societies.
They tested for irrationality in 
colonies of Temnothorax ants 
choosing between two nest sites that 
varied in attributes, such that neither 
nest site was clearly superior. In 
similar situations, individual animals 
show irrational changes in preference 
when a third relatively unattractive 
option is introduced. 
Edwards and Pratt’s ants are 
eusocial insect colonies, where sterile 
workers advance their inclusive 
fi tness largely through cooperative 
rearing of the queen’s offspring. As 
a result, selection has acted at the 
level of the whole colony to shape 
A new study suggests ant colonies 
can avoid irrational changes in 
preference that can be shown by 
individual animals and humans. Nigel 
Williams reports. 
Collective rationalityThe majority of people infected 
with T. cruzi show some sign or 
symptom at the time of infection and 
in a small number of cases acute 
Chagas disease can be fatal. But 
for the majority, the symptoms go 
unnoticed for years and those infected 
experience no further problems. It is 
estimated that approximately 
70 per cent of these people live with 
the parasite without their health being 
affected.
Nevertheless, in the chronic 
phase of the disease 30 per cent 
will develop problems in their heart, 
gastrointestinal tract and central 
nervous system that cause irreversible 
damage.
There are currently only two 
medicines to combat Chagas disease, 
both of which were developed 
more than 35 years ago and in 
investigations not specifi cally aimed 
at Chagas disease. Neither of these 
drugs can be used in pregnant 
women but the success rate reaches 
almost 100 per cent in newborns and 
infants. However, in older children, 
adolescents and adults, treatment 
is only 60–70 per cent effective and 
can have multiple side effects and, 
therefore, has to be taken under 
medical supervision. This means 
having a weekly check-up with a 
trained healthcare worker.
But, as the side effects are more 
common in older patients, many 
doctors have been reluctant to use the 
drugs in adults, although it has now 
been shown that the adverse effects 
can be manageable.
With the limited resources available 
in rural areas of Latin America to treat 
Chagas disease, medical teams are 
often unable to diagnose and treat the 
disease. New diagnostic tests, better 
medicines and cure tests urgently 
need to be developed to deal with this 
illness, say MSF.
Currently, MSF uses a rapid 
diagnostic test to detect cases. But, 
following WHO recommendations, all 
positive tests need to be confi rmed 
with two conventional laboratory 
serological assays. If there is any 
discrepancy between the two tests, a 
third laboratory test must be used to 
obtain a reliable result.
In areas such as rural Bolivia, where 
the incidence of the disease is high, 
the ideal would be to have a highly 
sensitive and specifi c rapid diagnostic 
test which would reveal whether the 
patient was infected or not in a short space of time and would not require 
specialised laboratories.
MSF says the Drugs for Neglected 
Diseases initiative (DNDi), of which it 
is a founder member, is working on 
possible alternative treatments to 
the two currently available. But 
these are a long way from being 
available and at low cost, and 
their effectiveness has yet to be 
demonstrated.
“There is an urgent need to develop 
new, less toxic, medicines which 
require a shorter course of treatment, 
are effective in the acute and chronic 
phases of the disease in both 
adults and children, and are safe for 
pregnant women,” says MSF.
MSF also highlights the major 
problem of determining whether 
treatment has been effective. “The 
current serological methods can take 
decades,” it says. “PCR techniques, based on genetic information, have 
a low sensitivity and specifi city for 
parasites, and they are only available 
in some research centres,” says MSF. 
“Development of rapid treatment tests 
which allow for the effectiveness of 
treatment to be measured and cure 
to be confi rmed in the fi rst two years 
after treatment for all age groups is 
essential.”
MSF also believes the research 
climate needs to change for 
neglected diseases. In 2006 the WHO 
Commission for Intellectual Property 
Rights, Innovation and Health 
recognised the failure of current 
incentives and fi nancing mechanisms 
for neglected diseases. “There is a 
need to identify new incentives for 
research and development and the 
fi nal price of health products to obtain 
better and new diagnostics and 
treatments,” says MSF. 
